^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
…the NCCN Panel recommends bevacizumab plus erlotinib for select patients with advanced RCC and papillary histology, including HLRCC (category 2A).
